CONTENTS

INVENTOR SEARCH

=> d ibib abs hitstr l6 1-3

L6 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:726752 HCAPLUS Full-text
DOCUMENT NUMBER: 147:111976
TITLE: Reversine increases the plasticity of lineage-committed mammalian cells
AUTHOR(S): Chen, Shuibing; Takanashi, Shinichi; Zhang, Qisheng; Xiong, Wen; Zhu, Shoutian; Peters, Eric C.; Ding, Sheng; Schultz, Peter G.
CORPORATE SOURCE: Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2007), 104(25), 10482-10487 CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Previously, a small mol., reversine, was identified that reverses lineage-committed murine myoblasts to a more primitive multipotent state. Here, we show that reversine can increase the plasticity of C2C12 myoblasts at the single-cell level and that reversine-treated cells gain the ability to differentiate into osteoblasts and adipocytes under lineage-specific inducing conditions. Moreover, reversine is active in multiple cell types, including 3T3E1 osteoblasts and human primary skeletal myoblasts. Biochem. and cellular expts. suggest that reversine functions as a dual inhibitor of nonmuscle myosin II heavy chain and MEK1, and that both activities are required for reversine's effect. Inhibition of MEK1 and nonmuscle myosin II heavy chain results in altered cell cycle and changes in histone acetylation status, but other factors also may contribute to the activity of reversine, including activation of the PI3K signaling pathway.
IT 656820-32-5, Reversine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reversine increases plasticity of lineage-committed mammalian cells)
RN 656820-32-5 HCAPLUS
CN 9H-Purine-2,6-diamine, N6-cyclohexyl-N2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:451560 HCAPLUS Full-text
DOCUMENT NUMBER: 142:478415
TITLE: Compositions and methods for inducing cell dedifferentiation
INVENTOR(S): Chen, Shuibing; Ding, Sheng; Schultz, Peter G.
PATENT ASSIGNEE(S): The Scripps Research Institute, USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047524	A2	20050526	WO 2004-US37686	20041110
WO 2005047524	A3	20051229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050176707	A1	20050811	US 2004-985645	20041110
EP 1682150	A2	20060726	EP 2004-800997	20041110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
JP 2007510752	T	20070426	JP 2006-539866	20041110
US 20070254884	A1	20071101	US 2007-577191	20070227
PRIORITY APPLN. INFO.:			US 2003-518947P	P 20031110
			WO 2004-US37686	W 20041110

OTHER SOURCE(S): MARPAT 142:478415

AB The present invention provides compns. and methods for dedifferentiating lineage committed mammalian cells.

IT 91-19-0D, Quinoxaline, derivs. 120-73-0D, Purine, derivs. 253-52-1D, Phthalazine, derivs. 253-82-7D, Quinazoline, derivs. 289-80-5D, Pyridazine, derivs.

289-95-2D, Pyrimidine, derivs. 290-37-9D, Pyrazine, derivs.
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(compns. and methods for inducing cell dedifferentiation)

RN 91-19-0 HCAPLUS
CN Quinoxaline (CA INDEX NAME)

RN 120-73-0 HCAPLUS
CN 9H-Purine (CA INDEX NAME)

RN 253-52-1 HCAPLUS
CN Phthalazine (CA INDEX NAME)



RN 253-82-7 HCAPLUS
CN Quinazoline (CA INDEX NAME)

RN 289-80-5 HCAPLUS
CN Pyridazine (CA INDEX NAME)

RN 289-95-2 HCAPLUS
CN Pyrimidine (CA INDEX NAME)

RN 290-37-9 HCAPLUS
CN Pyrazine (CA INDEX NAME)

IT 325167-28-0 325167-35-9 709609-12-1
852231-90-4 852231-92-6 852231-94-8
852231-96-0 852231-98-2 852232-01-0
852232-03-2 852232-05-4 852232-07-6
852232-11-2 852232-13-4
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(compns. and methods for inducing cell dedifferentiation)
RN 325167-28-0 HCAPLUS
CN 9H-Purine-2,6-diamine, N6-(cyclopropylmethyl)-N2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 325167-35-9 HCAPLUS
CN 9H-Purine-2,6-diamine, N6-cyclopentyl-N2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 709609-12-1 HCAPLUS
CN 9H-Purine-2,6-diamine, N6-ethyl-N2-[4-(4-morpholinyl)phenyl]- (CA INDEX

NAME)



RN 852231-90-4 HCAPLUS
CN 9H-Purine-2,6-diamine, N6-[1-[(4-methoxyphenyl)methyl]-4-piperidinyl]-N2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 852231-92-6 HCAPLUS
CN 9H-Purine-2,6-diamine, N6-[1-[[4-(dimethylamino)phenyl]methyl]-4-piperidinyl]-N2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 852231-94-8 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-[4-(4-morpholinyl)phenyl]-N6-[1-(2-phenylpropyl)-4-piperidinyl]- (CA INDEX NAME)



RN 852231-96-0 HCAPLUS
CN 9H-Purine-2,6-diamine, N6-[1-[(2,3-dihydro-2-benzofuranyl)methyl]-4-piperidinyl]-N2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 852231-98-2 HCAPLUS
CN 9H-Purine-2,6-diamine, N6-[1-(2,2-diphenylethyl)-4-piperidinyl]-N2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 852232-01-0 HCAPLUS
CN 9H-Purine-2,6-diamine, N6-(1,5-dimethylhexyl)-N2-[4-(4-morpholinyl)phenyl]-

(CA INDEX NAME)



RN 852232-03-2 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[2-[[4-(4-morpholinyl)phenyl]amino]-9H-purin-6-yl]amino]-, ethyl ester (CA INDEX NAME)



RN 852232-05-4 HCAPLUS
CN 9H-Purine-2,6-diamine, N6-[2-(2-cyclohexen-1-yl)ethyl]-N2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 852232-07-6 HCAPLUS
CN 9H-Purine-2,6-diamine, N6-(cyclohexylmethyl)-N2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 852232-11-2 HCAPLUS
CN 9H-Purine-2,6-diamine, N6-(4-methoxyphenyl)-N2-[4-(4-morpholinyl)phenyl]-
(CA INDEX NAME)



RN 852232-13-4 HCAPLUS
CN 9H-Purine-2,6-diamine, N2-[4-(4-morpholinyl)phenyl]-N6-(3-phenoxyphenyl)-
(CA INDEX NAME)



IT 108-91-8, Cyclohexylamine, reactions 1651-29-2,
2-Fluoro-6-chloropurine 2524-67-6, 4-Morpholinoaniline
RL: RCT (Reactant); RACT (Reactant or reagent)
(compns. and methods for inducing cell dedifferentiation)
RN 108-91-8 HCAPLUS
CN Cyclohexanamine (CA INDEX NAME)

RN 1651-29-2 HCAPLUS
CN 9H-Purine, 6-chloro-2-fluoro- (CA INDEX NAME)



RN 2524-67-6 HCAPLUS
CN Benzenamine, 4-(4-morpholinyl)- (CA INDEX NAME)



IT 852231-88-0P, 2-Fluoro-6-cyclohexylamino-purine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(compns. and methods for inducing cell dedifferentiation)
RN 852231-88-0 HCAPLUS
CN 9H-Purin-6-amine, N-cyclohexyl-2-fluoro- (CA INDEX NAME)



IT 656820-32-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(compns. and methods for inducing cell dedifferentiation)
RN 656820-32-5 HCAPLUS
CN 9H-Purine-2,6-diamine, N6-cyclohexyl-N2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:996204 HCAPLUS Full-text
DOCUMENT NUMBER: 140:160988
TITLE: Dedifferentiation of Lineage-Committed Cells by a Small Molecule
AUTHOR(S): Chen, Shuibing; Zhang, Qisheng; Wu, Xu; Schultz, Peter G.; Ding, Sheng
CORPORATE SOURCE: Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
SOURCE: Journal of the American Chemical Society (2004), 126(2), 410-411
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Combinatorial libraries were screened for mols. that induce mouse myogenic lineage committed cells to dedifferentiate in vitro. A 2,6-disubstituted purine, reversine, was discovered that induces lineage reversal of C2C12 cells to become multipotent progenitor cells which can redifferentiate into osteoblasts and adipocytes. This and other such mols. are likely to provide new insights into the mol. mechanisms that control cellular dedifferentiation and may ultimately be useful to in vivo stem cell biol. and therapy.

IT 656820-32-5, Reversine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dedifferentiation of lineage-committed cells by small mol. reversine)

RN 656820-32-5 HCAPLUS
CN 9H-Purine-2,6-diamine, N6-cyclohexyl-N2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

RESULTS FROM REGISTRY, CAPLUS, AND USPATFULL

```
=> d que stat l26
L16             STR
```



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  22

STEREO ATTRIBUTES: NONE
L18         131 SEA FILE=REGISTRY SSS FUL L16
L22          15 SEA FILE=REGISTRY ABB=ON  L18 AND NR=4 AND NRS=3
L23           3 SEA FILE=REGISTRY ABB=ON  L22 AND N=6
L24           1 SEA FILE=HCAPLUS ABB=ON  L23
L25           1 SEA FILE=USPATFULL ABB=ON  L23
L26           2 DUP REMOV L24 L25 (0 DUPLICATES REMOVED)


=> d ibib abs hitstr l26 1-2

L26  ANSWER 1 OF 2  USPATFULL on STN
ACCESSION NUMBER:       2003:184082  USPATFULL  Full-text
TITLE:                  Purine derivatives inhibitors of tyrosine protein
                        kinase SYK
INVENTOR(S):            Collingwood, Stephen Paul, Horsham, UNITED KINGDOM
                        Hayler, Judy, Horsham, UNITED KINGDOM
                        Le Grand, Darren Mark, Horsham, UNITED KINGDOM
                        Mattes, Henri, Brunstatt, FRANCE
                        Menear, Keith Allan, Horsham, UNITED KINGDOM
                        Walker, Clive Victor, Horsham, UNITED KINGDOM
                        Cockcroft, Xiao-Ling, Horsham, UNITED KINGDOM
PATENT ASSIGNEE(S):     Novartis AG, Basel, SWITZERLAND (non-U.S. corporation)

                             NUMBER       KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 6589950         B1   20030708
                        WO 2001009134           20010208
APPLICATION INFO.:      US 2002-48577           20020319  (10)
                        WO 2000-EP7311          20000728

                              NUMBER        DATE
                        ------------------ --------
PRIORITY INFORMATION:   GB 1999-18035      19990730
DOCUMENT TYPE:          Utility
```

FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Berch, Mark L.
LEGAL REPRESENTATIVE: Lopez, Gabriel, Dohmann, George R.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1895
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are compounds of the formula ##STR1##

in free or salt form, wherein X, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of inflammatory or obstructive airways disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **325166-09-4P 325166-51-6P 325166-64-1P**
(target compound; preparation of anilinopurine tyrosine protein kinase syk inhibitors by addition of anilines and amines, alcs., or thiols to dichloropurines)
RN 325166-09-4 USPATFULL
CN 9H-Purin-2-amine, 6-ethoxy-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 325166-51-6 USPATFULL
CN 9H-Purin-2-amine, 6-[(1-methylethyl)thio]-N-[4-(4-morphol inyl)phenyl]- (CA INDEX NAME)



RN 325166-64-1 USPATFULL
CN 9H-Purin-2-amine, 6-(ethylthio)-N-[4-(4-morphol inyl)phenyl]- (CA INDEX NAME)



L26 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:101141 HCAPLUS Full-text
DOCUMENT NUMBER: 134:163051
TITLE: Preparation of anilinopurine derivatives as inhibitors of tyrosine protein kinase syk
INVENTOR(S): Collingwood, Stephen Paul; Hayler, Judy; Le Grand, Darren Mark; Mattes, Henri; Menear, Keith Allan; Walker, Clive Victor; Cockcroft, Xiao-ling
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009134	A1	20010208	WO 2000-EP7311	20000728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 255268	B	20060521	TW 2000-89114515	20000720
TW 274754	B	20070301	TW 2005-94101835	20000720
CA 2379560	A1	20010208	CA 2000-2379560	20000728
BR 2000012888	A	20020409	BR 2000-12888	20000728
EP 1200435	A1	20020502	EP 2000-953112	20000728
EP 1200435	B1	20031001		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 200200234	T2	20020621	TR 2002-234	20000728
HU 2002001935	A2	20021128	HU 2002-1935	20000728
HU 2002001935	A3	20050228		
JP 2003506375	T	20030218	JP 2001-514337	20000728
AT 251160	T	20031015	AT 2000-953112	20000728
AU 767349	B2	20031106	AU 2000-65677	20000728
PT 1200435	T	20040227	PT 2000-953112	20000728
NZ 516667	A	20040528	NZ 2000-516667	20000728
ES 2208395	T3	20040616	ES 2000-953112	20000728
RU 2248977	C2	20050327	RU 2002-103305	20000728
CN 1213047	C	20050803	CN 2000-811026	20000728
SK 285730	B6	20070706	SK 2002-126	20000728
NO 2002000467	A	20020320	NO 2002-467	20020129
ZA 2002000783	A	20030212	ZA 2002-783	20020129
MX 2002001102	A	20020820	MX 2002-1102	20020130
US 6589950	B1	20030708	US 2002-48577	20020319
JP 2007217426	A	20070830	JP 2007-130684	20070516
PRIORITY APPLN. INFO.:			GB 1999-18035	A 19990730
			JP 2001-514337	A3 20000728
			WO 2000-EP7311	W 20000728
OTHER SOURCE(S):	MARPAT 134:163051			

GI



I



II

AB The title compds. (I) [wherein X = O, S, or NR5; R1 = (un)substituted (cyclo)alkyl, alkenyl, benzocycloalkyl, cycloalkylalkyl, or aralkyl; R2, R3, and R4 = independently H, halo, (halo)alkyl, alkoxy, carboxy, alkoxycarbonyl(alkyl), carboxyalkyl, or (un)substituted amino, sulfamoyl(alkyl), or carbamoyl; or two of R2, R3, and R4 form a carbocyclic or heterocyclic ring together with the C atoms to which they are attached; R5 = H or alkyl] in free or salt form were prepared for use as pharmaceuticals, particularly for the treatment of inflammatory or obstructive airways disease. For example, cyclopropylamine and N,N-diisopropylethylamine were added to 2,6-dichloropurine in n-BuOH to give 6-cyclopropylamino-2-chloropurine. The chloropurine was stirred with 4-morpholinoaniline in the presence of N,N-diisopropylethylamine in NMP at 130°C for 48 h to give II, which inhibited phosphorylation by syk kinase with an IC50 of 9 nM.

IT 325166-09-4P 325166-51-6P 325166-64-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of anilinopurine tyrosine protein kinase syk inhibitors by addition of anilines and amines, alcs., or thiols to dichloropurines)

RN 325166-09-4 HCAPLUS

CN 9H-Purin-2-amine, 6-ethoxy-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 325166-51-6 HCAPLUS

CN 9H-Purin-2-amine, 6-[(1-methylethyl)thio]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 325166-64-1 HCAPLUS
CN 9H-Purin-2-amine, 6-(ethylthio)-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

SEARCH HISTORY

```
=> d his ful

     (FILE 'HOME' ENTERED AT 17:08:15 ON 06 MAR 2009)

     FILE 'HCAPLUS' ENTERED AT 17:08:30 ON 06 MAR 2009

     FILE 'HCAPLUS' ENTERED AT 17:08:43 ON 06 MAR 2009
                  E CHEN SHUIBING/AU
L1           14 SEA ABB=ON  "CHEN SHUIBING"/AU
                  E DING SHENG/AU
L2          126 SEA ABB=ON  "DING SHENG"/AU
                  E SCHULTZ PETER G/AU
L3          475 SEA ABB=ON  "SCHULTZ PETER G"/AU
L4            5 SEA ABB=ON  L1 AND L2 AND L3
                  SELECT RN L4 4

     FILE 'REGISTRY' ENTERED AT 17:09:53 ON 06 MAR 2009
L5           26 SEA ABB=ON  (108-91-8/BI OR 120-73-0/BI OR 1651-29-2/BI OR
                  2524-67-6/BI OR 253-52-1/BI OR 253-82-7/BI OR 289-80-5/BI OR
                  289-95-2/BI OR 290-37-9/BI OR 325167-28-0/BI OR 325167-35-9/BI
                  OR 656820-32-5/BI OR 709609-12-1/BI OR 852231-88-0/BI OR
                  852231-90-4/BI OR 852231-92-6/BI OR 852231-94-8/BI OR 852231-96
                  -0/BI OR 852231-98-2/BI OR 852232-01-0/BI OR 852232-03-2/BI OR
                  852232-05-4/BI OR 852232-07-6/BI OR 852232-11-2/BI OR 852232-13
                  -4/BI OR 91-19-0/BI)

     FILE 'HCAPLUS' ENTERED AT 17:10:00 ON 06 MAR 2009
L6            3 SEA ABB=ON  L4 AND L5
                  D TI 1-3
                  D IBIB ABS HITSTR L6 2

     FILE 'REGISTRY' ENTERED AT 17:11:50 ON 06 MAR 2009
L7                STRUCTURE  325167-35-9
L8            3 SEA SSS SAM L7
                  D SCAN
L9                STR L7
L10           3 SEA SSS SAM L9
L11         139 SEA SSS FUL L9
L12               STR L9
L13               STR L9
L14           0 SEA SSS SAM L13
L15           0 SEA SSS FUL L13
L16               STR L13
L17           3 SEA SSS SAM L16
L18         131 SEA SSS FUL L16
L19          17 SEA ABB=ON  L18 AND N=6
L20          10 SEA ABB=ON  L19 AND O=1
L21           0 SEA ABB=ON  L20 AND C=15
                  D L20 1-10
L22          15 SEA ABB=ON  L18 AND NR=4 AND NRS=3
L23           3 SEA ABB=ON  L22 AND N=6

     FILE 'HCAPLUS' ENTERED AT 17:28:01 ON 06 MAR 2009
L24           1 SEA ABB=ON  L23
```

FILE 'USPATFULL' ENTERED AT 17:28:12 ON 06 MAR 2009
L25 1 SEA ABB=ON L23

FILE 'HCAPLUS, USPATFULL' ENTERED AT 17:28:25 ON 06 MAR 2009
L26 2 DUP REMOV L24 L25 (0 DUPLICATES REMOVED)

FILE HOME

FILE HCAPLUS

FILE COVERS 1907 - 6 Mar 2009 VOL 150 ISS 11
FILE LAST UPDATED: 5 Mar 2009 (20090305/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAR 2009 HIGHEST RN 1116197-74-0
DICTIONARY FILE UPDATES: 5 MAR 2009 HIGHEST RN 1116197-74-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 5 Mar 2009 (20090305/PD)
FILE LAST UPDATED: 5 Mar 2009 (20090305/ED)
HIGHEST GRANTED PATENT NUMBER: US7500272
HIGHEST APPLICATION PUBLICATION NUMBER: US20090064384

CA INDEXING IS CURRENT THROUGH 5 Mar 2009 (20090305/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 5 Mar 2009 (20090305/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2008
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2008

USPATFULL now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.